Zobrazeno 1 - 10
of 29
pro vyhledávání: '"Matthias Grell"'
Autor:
Simon L. Goodman, Ann L.B. Seynhaeve, Sandra T. van Tiel, Curzio Rüegg, Timo L.M. ten Hagen, Gisela aan de Wiel-Ambagtsheer, Matthias Grell, Michael Meyring, Ernst A. de Bruijn, Alexander M.M. Eggermont
Publikováno v:
International Journal of Cancer, 132(11), 2694-2704. Wiley-Liss Inc.
Isolated limb perfusion (ILP) with melphalan and tumor necrosis factor (TNF)-α is used to treat bulky, locally advanced melanoma and sarcoma. However, TNF toxicity suggests a need for better-tolerated drugs. Cilengitide (EMD 121974), a novel cyclic
Autor:
M Ameyar, Y Monnier, Jeannine Bamat, G. Bieler, Ferdy J. Lejeune, Curzio Rüegg, L Ponsonnet, Meriem Hasmim, Simon L. Goodman, N Imaizumi, Matthias Grell, Salem Chouaib
Publikováno v:
Oncogene
Oncogene, Nature Publishing Group, 2007, 26 (39), pp.5722-32. ⟨10.1038/sj.onc.1210354⟩
Oncogene, 2007, 26 (39), pp.5722-32. ⟨10.1038/sj.onc.1210354⟩
Oncogene, Nature Publishing Group, 2007, 26 (39), pp.5722-32. ⟨10.1038/sj.onc.1210354⟩
Oncogene, 2007, 26 (39), pp.5722-32. ⟨10.1038/sj.onc.1210354⟩
International audience; Tumor necrosis factor (TNF) is a pro-inflammatory cytokine exerting pleiotropic effects on endothelial cells. Depending on the vascular context it can induce endothelial cell activation and survival or death. The microenvironm
Autor:
Carmen Kolle, Matthias Grell, Gudrun Zimmermann, Jeannette Gerspach, Heiner Böttinger, Alex Götz
Publikováno v:
Microscopy Research and Technique. 50:243-250
Tumor necrosis factor (TNF) exists in two bioactive forms, the membrane integrated form and the proteolytically derived soluble cytokine. Both forms of TNF are involved in a variety of different physiological and pathophysiological situations. Here w
Publikováno v:
Cytokine & Growth Factor Reviews. 10:15-26
Just four years ago the first two members of a new family of molecules involved in signal transduction by members of the TNF receptor superfamily were described and designated TNF Receptor Associated Factors (TRAFs). In the meantime six human and mur
Autor:
Craig Smith, Harald Wajant, Elvira Haas, Frank Mühlenbeck, Matthias Grell, Ralph Schwenzer, Gisela Schubert, Peter Scheurich
Publikováno v:
Journal of Biological Chemistry. 273:33091-33098
In this study we show that TRAIL (tumor necrosis factor-related apoptosis-inducing ligand), also called Apo2L, activates the c-Jun N-terminal kinase (JNK). Interestingly, TRAIL-induced JNK activation occurs in a cell type-specific manner. In HeLa cel
Publikováno v:
Proceedings of the National Academy of Sciences. 95:570-575
Tumor necrosis factor (TNF) can induce a variety of cellular responses at low picomolar concentrations. This is in apparent conflict with the published dissociation constants for TNF binding to TNF receptors in the order of 100–500 pM. To elucidate
Publikováno v:
European Journal of Immunology. 28:257-263
Tumor necrosis factor (TNF) mediates its biological effects by binding to two distinct but homologous receptor molecules. The type 1 receptor (TNF-R1) has been shown to be essential and sufficient for most cellular responses to soluble TNF. In contra
Autor:
Horst Bluethmann, Matthias Grell, Manolis Pasparakis, Sabine Küsters, Eleni Douni, Albrecht Wendel, Klaus Pfizenmaier, George Kollias, Gisa Tiegs, Lena Alexopoulou, Gerald Künstle
Publikováno v:
European Journal of Immunology. 27:2870-2875
The significance of tumor necrosis factor receptor 1 (TNFR1) for TNF function in vivo is well documented, whereas the role of TNFR2 so far remains obscure. In a model of concanavalin A (Con A)-induced, CD4+ T cell-dependent experimental hepatitis in
Publikováno v:
Cytokine & Growth Factor Reviews. 7:271-277
The 6th International Congress on Tumor Necrosis Factors and Related Molecules was held in Faliraki, Island of Rhodes, Greece, 8–12 May, 1996. This review summarizes the topics addressed and highlights some of the major advances presented during th